Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the efficacy of intense pulsed light (IPL) therapy for the treatment of dry eye disease. One eye of the participant will be randomized to receive the IPL treatment.


Clinical Trial Description

Dry eye disease (DED) affects tears and the front surface of the eye. Patients who have DED can experience symptoms of discomfort, blurry vision, redness, and pain. DED can also cause tears to become unstable which could result in damage to the front surface of the eye.

There are two types of DED. The one the investigators are studying is called evaporative dry eye disease. This type of DED occurs because the pores on the eyelids are not functioning properly. In preliminary studies, a new treatment called Intense Pulsed Light (IPL) has shown promise to reduce signs and symptoms of evaporative DED. IPL is a non-invasive and non-laser light treatment that was approved in 1995 by the FDA for dermatology. It is commonly used for treatment of facial rosacea, acne, and hair, wrinkle and lesion removal. It is not currently approved for the treatment of dry eye disease. This treatment is thought to provide relief of evaporative DED symptoms and improve the expression of the pores on the edge of the eyelid. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03089580
Study type Interventional
Source University of Michigan
Contact
Status Completed
Phase N/A
Start date March 25, 2017
Completion date November 1, 2018

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Withdrawn NCT03952481 - Effect of Lifitegrast 5% on Tear Film Markers Phase 4
Withdrawn NCT05169931 - Clinical Efficacy of Amniotic Membrane Extract Eye Drops in Dry Eye Treatment Early Phase 1